Tag Archive for: BioPharma

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

/in

Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a […]

Read more

Poolbeg Pharma plc – Board Role Change and Launch of Employee Performance Incentive Plan

/in

15 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, “Poolbeg” or the “Company”), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces a change of Board role and the Remuneration Committee’s approval of the adoption of an Employee Performance Incentive Plan (“EIP”) for a number of […]

Read more

Poolbeg Pharma plc – Independent Research Confirms >$10bn Market Opportunity for POLB 001 as a Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

/in

Former Amryt team’s arrival supports increasing focus upon Rare and Orphan Diseases 12 February 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, today announces that independent research[i] [ii] conducted on behalf of Poolbeg confirms a >$10 billion market opportunity […]

Read more

JPM ’24: The year’s healthcare barometer gives a more sunny outlook

/in

The JPM Healthcare Conference of 2024 may not have witnessed a mega-merger announcement, but there is anticipation that the M&A market could pick up this year, with predictions that the economic headwinds of recent years could turn into tailwinds.  The recent M&A Firepower report from EY, formerly known as Ernst & Young, has forecast a […]

Read more

Poolbeg Pharma plc – Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI

/in

RSV drug candidates with the highest probability of success prioritised 20 December 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces the positive outputs from the lab-based analysis and successful prioritisation of the Respiratory Syncytial Virus […]

Read more